Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And we think that this new platform that we just released just several weeks ago is going to be a really good answer to stabilizing the returning customer base with PetMeds |
| This drives greater engagement and strengthens our recurring sales base |
| And so as we get better at go-to-market, as we get better at marketing the right brands to our customers, that should continue to be a really good trend for the business |
| We believe these additional food options provide us the ability to interact with our customers more often, increase the average order size and enhance the lifetime value of each customer |
| We have talked about our key performance indicators for the transformation of the business: successfully providing more product offerings to our current customers, increasing our recurring customer base and driving recurring revenues |
| We believe that our new AutoShip platform which was recently launched, will help facilitate the long-term compounded benefit and expanded customer loyalty by delivering exceptional value |
| We're excited about continuing to articulate our milestones along this journey |
| This new AutoShip & Save capability enhances our current capabilities to include more pet parent control over their ordering experience, including activities like controlling the subscription duration, pausing or accelerating a subscription and adding additional products |
| Our AutoShip & Save and PetPlus programs grew to 52% of our revenue during this last fiscal quarter, a substantial increase from 42% of revenue for the same time last year |
| This will deliver more value to new pet parents as well as our existing 2 million customers |
| We've continued to grow our recurring revenue, including AutoShip & Save sales and PetCareRx membership sales as a percentage of total sales |
| Now we believe that 405 is better than 450 |
| The announcement of adding a new premium food brand, along with a major upgrade to our AutoShip & Save infrastructure represent significant milestones in the journey to transform PetMeds into a trusted pet health expert |
| Additionally, we are enhancing our cross-sell initiatives through our e-mail CRM, call center and website |
| It's our fastest-growing category |
| For the quarter ending December 31, 2023, PetMeds delivered sales of $65.3 million compared to sales of $58.9 million in the prior year, an increase of 11% year-over-year, including from our recent acquisition of PetCareRx |
| And we've seen a large growth in our food sales as a percentage of sales which is very low |
| Recurring sales as a percentage of total sales was 52% in the quarter, up sequentially from 51% in the prior quarter and up from 42% for the same period last year |
| A key business model driver for the PetMeds business is to expand the number and types of products our core prescription customer base buys from us or will buy from us on a recurring basis |
| Returning customers accounted for sales of $57.7 million during the quarter, reflecting a growth of 8% year-over-year related to the addition of the PetCareRx business |
| Our customers are very health conscious |
| Reorder sales were $57.7 million for the quarter, an increase of 8% compared to reorder sales of $53.3 million in the same period last year |
| We believe the more products that pet parent uses on our AutoShip program, the more loyal they become |
| And this AutoShip & Save platform, we think, is going to be a key future unlock to really stabilize that base because it's a much more stable platform |
| While having to restate is really disappointing, we are, as Matt and I have mentioned, committed to operating with the highest standards of transparency and making sure that we provide transparency and integrity |
| Along those lines, we are excited to announce the addition of another major food brand of PetMeds in the coming months |
| And that's a huge deal for our customers |
| The most significant impact to the income statement is expected to be a decrease in general and administrative expense for fiscal year 2023 in the range of $6 million to $8 million and the corresponding increase in net income for the same period |
| The growth was due to incremental sales from the acquisition of PetCareRx partially offset by declines in PetMeds legacy new order and reorder sales |
| We'd like to be a lot higher than that |
| Statement |
|---|
| We continue to experience a single-digit decline in PetMeds legacy reorder sales |
| The restatement and the delay in this quarter's 10-Q filing are due to errors in the accounting treatment related to certain previously reported tax-related items |
| As a result of the level of administrative effort and time associated with completing the restatement, the company will experience a delay in the filing of its quarterly report on Form 10-Q for the quarter ended December 31, 2023 and expects to file a notification of late filing with the SEC |
| Additionally, due to the administrative burden and the process required for a multiyear restatement, our 10-Q for fiscal year 2024's third quarter ended December 31, 2023, will be delayed |
| Yes, I think in the call, you obviously noted that the returning core PetMeds customer base, we noted, is declining relatively at the same rate from previous quarters |
| The decline year-over-year is primarily due to onetime promotions in the same period last year that we tested and intentionally did not repeat as they did not attract high order value customers |
| To reiterate, this quarter, due to the restatement process, we cannot comment on numbers below the gross profit line as the restatement could potentially impact G&A |
| Now it sounds like it's obviously going to be quite a bit more than that |
| Although it was unfortunate news today regarding the tax liability issues and the accounting change, we hope that, that doesn't overshadow our excitement as a management team about the future of PetMeds as we transform from a single category pet medication business to a broader pet health expert business |
Please consider a small donation if you think this website provides you with relevant information